Verici Dx (LON:VRCI) Shares Up 5.9% – Should You Buy?

Verici Dx plc (LON:VRCI)’s stock price shot up 5.9% during mid-day trading on Thursday . The company traded as high as GBX 0.45 and last traded at GBX 0.45. 980,794 shares changed hands during trading, a decline of 38% from the average session volume of 1,571,910 shares. The stock had previously closed at GBX 0.43.

Verici Dx Stock Down 17.2%

The company has a debt-to-equity ratio of 11.36, a quick ratio of 8.49 and a current ratio of 0.91. The firm has a market cap of £5.33 million, a PE ratio of -0.12 and a beta of 1.30. The stock has a fifty day moving average price of GBX 0.46 and a 200-day moving average price of GBX 0.61.

Verici Dx Company Profile

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.